logo
Share SHARE
FONT-SIZE Plus   Neg

Opnet Technologies Lowers Q4 Guidance

Opnet Technologies, Inc. (OPNT) announced that it lowered its fourth-quarter outlook. Looking ahead for the fourth-quarter, the company now expects GAAP net income per share to be in the range $0.16 and $0.17, Non-GAAP net income per share of $0.20 and $0.21 and revenue of $44.4 million to $44.6 million. Earlier, the company had expected GAAP earnings of $0.17 to $0.29 per share, adjusted earnings to be in a range of $0.20 to $0.32 per share, revenues of $45 million - $49 million.

Analysts polled by Thomson Reuters expect the company to report earnings of $0.26 per share on revenues of $46.99 million for the fourth-quarter. Analysts' estimates typically exclude special items.

The company now expects revenue for fiscal 2012 to be in the range of $172.6 million to $172.8 million, compared to prior outlook of revenues between $173 million and $177 million. Analysts expect the company to report revenues of $175.16 million for fiscal 2012.

Marc Cohen, OPNET's Chairman and CEO, stated, " Our Q4 estimated revenue results were affected by last minute purchasing delays associated with approximately $2.4 million of deals we expected to close during the quarter. Two of these deals, which account for approximately 56% of the delayed total, have been partially booked and we expect the remaining portion of both deals to be booked by the end of April. The deals that make up the remaining delayed total are all in process, and are also expected to close by the end of April."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The holiday throng seeking to take a flight out to their preferred destinations at the at New York's Kennedy International Airport ahead of the Memorial Day holiday were in for a rude shock. Technology played a spoilsport, as a computer system broke down Sunday evening at a terminal, causing flight delays and cancellations that resulted in manual check-in process for thousands of holiday passeng The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology.
comments powered by Disqus
Follow RTT